stockrowIncyte Corporation
INCYIncyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −277.9%
- Free cash flow
- −233.0%
- Total debt
- −10.5%
Quarter to September 2026, against a year earlier
Follow INCY
Alert me
Incyte Corporation (INCY) Revenue growth
Incyte Corporation's revenue growth over the twelve months to 30 September 2026 was 24.9%, up 3.7 percentage points from fiscal 2025 (21.2%). Over the past ten years it has ranged from 8.87% (fiscal 2023) to 47.4% (fiscal 2015); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 7.42% and above the Healthcare sector median of 8.15%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 21.2% | 6.46 |
| FY2024 | 14.8% | 5.89 |
| FY2023 | 8.87% | (4.80) |
| FY2022 | 13.7% | 1.69 |
| FY2021 | 12.0% | (11.55) |
| FY2020 | 23.5% | 8.82 |
| FY2019 | 14.7% | (7.79) |
| FY2018 | 22.5% | (16.43) |
| FY2017 | 38.9% | (7.77) |
| FY2016 | 46.7% | (0.66) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 14.0% | (23.72) |
| Jun 2026 | 37.7% | 16.85 |
| Mar 2026 | 20.9% | (6.97) |
| Dec 2025 | 27.8% | 7.79 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| INSM Insmed, Inc. compare | 240.0% |
| ASND Ascendis Pharma A/S compare | 126.0% |
| ROIV Roivant Sciences Ltd. compare | 102.1% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 56.2% |
| INCY Incyte Corporation | 24.9% |
| GMAB Genmab A/S Sponsored ADR compare | 19.8% |
| JAZZ Jazz Pharmaceuticals PLC compare | 13.5% |
| EXEL Exelixis, Inc. compare | 9.12% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| Biotechnology industry median | 7.42% |
| Healthcare sector median | 8.15% |
| Market median | 7.72% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement